News headlines about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Alimera Sciences earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.0111398804781 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s rankings:
Alimera Sciences (NASDAQ:ALIM) traded down 2.38% during trading on Wednesday, hitting $1.23. 241,796 shares of the company traded hands. Alimera Sciences has a one year low of $1.03 and a one year high of $1.72. The firm’s market cap is $84.93 million. The firm has a 50 day moving average of $1.36 and a 200 day moving average of $1.42.
Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. The business’s revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.17) earnings per share. On average, analysts expect that Alimera Sciences will post ($0.21) earnings per share for the current fiscal year.
Several analysts have commented on the stock. HC Wainwright set a $5.00 target price on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Tuesday, July 11th. Cowen and Company reiterated a “buy” rating and issued a $3.00 price target on shares of Alimera Sciences in a report on Tuesday, July 11th. Zacks Investment Research lowered shares of Alimera Sciences from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Finally, ValuEngine upgraded shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Alimera Sciences has an average rating of “Hold” and an average target price of $3.38.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.